We are live on ! Find out more
TVRD

Tvardi Therapeutics
TVRD

114 hedge funds and large institutions have $296M invested in Tvardi Therapeutics in 2017 Q1 according to their latest regulatory filings, with 31 funds opening new positions, 36 increasing their positions, 29 reducing their positions, and 11 closing their positions.

New
Increased
Maintained
Reduced
Closed

200% more funds holding in top 10

Funds holding in top 10: 1 → 3 (+2)

182% more first-time investments, than exits

New positions opened: 31 | Existing positions closed: 11

130% more capital invested

Capital invested by funds: $129M → $296M (+$167M)

24% more repeat investments, than reductions

Existing positions increased: 36 | Existing positions reduced: 29

13% more funds holding

Funds holding: 101 → 114 (+13)

0.31% more ownership

Funds ownership: 1.41% → 1.72% (+0.31%)

25% less call options, than puts

Call options by funds: $11.2M | Put options by funds: $15.1M

Holders
114
Holders Change
+13
Holders Change %
+12.87%
% of All Funds
2.84%
Holding in Top 10
3
Holding in Top 10 Change
+2
Holding in Top 10 Change %
+200%
% of All Funds
0.07%
New
31
Increased
36
Reduced
29
Closed
11
Calls
$11.2M
Puts
$15.1M
Net Calls
-$3.83M
Net Calls Change
-$5.03M

Top Buyers

Rank Fund Capital Flow
1
BlackRock
BlackRock
New York
+$20.9M
2
Susquehanna International Group
Susquehanna International Group
Pennsylvania
+$13.3M
3
Fidelity Investments
Fidelity Investments
Massachusetts
+$12.6M
4
RCP
Rho Capital Partners
New York
+$7.42M
5
Jennison Associates
Jennison Associates
New York
+$4.45M

Top Sellers

Rank Fund Capital Flow
1
Allianz Asset Management
Allianz Asset Management
Germany
-$2.07M
2
NC
Nexthera Capital
New York
-$1.93M
3
DCM
DAFNA Capital Management
California
-$1.69M
4
CWG
C WorldWide Group
Denmark
-$1.56M
5
OM
Opaleye Management
Massachusetts
-$1.34M
Name Holding Trade Value Shares
Change 		Change in
Stake
TRCT
101
Tower Research Capital (TRC)
New York
$13K -$15K -28 -60%
WEC
102
Winslow Evans & Crocker
Massachusetts
$12.5K +$10.2K +19 New
HCM
103
Horrell Capital Management
Arkansas
$9K – – –
Nisa Investment Advisors
104
Nisa Investment Advisors
Missouri
$9K +$7.48K +14 New
CTC
105
Central Trust Company
Missouri
$5K +$3.74K +7 New
SPIA
106
Steward Partners Investment Advisory
New York
$5K +$4.27K +8 New
DADC
107
D.A. Davidson & Co
Montana
$2K +$1.6K +3 New
MAM
108
Meeder Asset Management
Ohio
$1K -$24K -45 -96%
MTIP
109
Magee Thomson Investment Partners
California
$1K -$1.07K -2 -67%
AIM
110
Advantage Investment Management
Iowa
$1K – – –
KF
111
Krilogy Financial
Missouri
$1K – – –
NFG
112
Next Financial Group
Texas
$1K +$534 +1 New
PA
113
Parallel Advisors
California
$1K +$534 +1 New
TWA
114
TCI Wealth Advisors
Arizona
$1K +$1.07K +2 New
BNP Paribas Financial Markets
115
BNP Paribas Financial Markets
France
$405 -$1.6K -3 -75%
Squarepoint
116
Squarepoint
New York
– -$820K -2,452 Closed
EIM
117
Essex Investment Management
Massachusetts
– -$516K -1,541 Closed
PCM
118
Prelude Capital Management
New York
– -$172K -514 Closed
Millennium Management
119
Millennium Management
New York
– -$152K -455 Closed
CS
120
Credit Suisse
Switzerland
– -$145K -435 Closed
WMSA
121
Weiss Multi-Strategy Advisers
New York
– -$93K -278 Closed
CSS
122
Cubist Systematic Strategies
Connecticut
– -$19K -55 Closed
SEI Investments
123
SEI Investments
Pennsylvania
– -$15K -44 Closed
GEA
124
Glen Eagle Advisors
New Jersey
– -$10.7K -32 Closed
MWM
125
MinichMacGregor Wealth Management
New York
– -$4K -14 Closed
2 3 4
5
6

TVRD Hedge Fund Activity: Q1 2017 in Review

114 of the 4,018 institutional investors tracked by Wall St. Rank reported a position in Tvardi Therapeutics (TVRD) for Q1 2017, worth a combined $296M — up 130% from $129M a quarter earlier.

Buyers outnumbered sellers: 31 funds opened new TVRD positions and 11 closed out — a net gain of 20 holders — while 36 added to existing stakes and 29 trimmed.

The largest buyer was BlackRock, adding an estimated $20.9M. The largest seller was Allianz Asset Management, cutting an estimated $2.07M.

  • 114 institutional investors held Tvardi Therapeutics (TVRD) as of Q1 2017, up from 101 in Q4 2016.
  • Funds reported $296M of Tvardi Therapeutics stock for Q1 2017, up 130% quarter-over-quarter.
  • 31 funds opened new Tvardi Therapeutics positions in Q1 2017 and 11 closed out, a net change of +20 holders.
  • The largest Tvardi Therapeutics buyer in Q1 2017 was BlackRock, an estimated $20.9M added.
  • The largest Tvardi Therapeutics seller in Q1 2017 was Allianz Asset Management, an estimated $2.07M sold.

Based on aggregated 13F filings for Q1 2017.